Mitochondrial fusion and fission regulation in Parkinson’s Disease by Santos, Daniel Ferreira dos
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEPARTAMENTO DE CIÊNCIAS DA VIDA 
FACULDADE DE CIÊNCIAS E TECNOLOGIA 
UNIVERSIDADE DE COIMBRA 
Mitochondrial fusion and 
fission regulation in 
Parkinson’s Disease 
 
Dissertação apresentada à Universidade de 
Coimbra para cumprimento dos requisitos 
necessários à obtenção do grau de Mestre em 
Biologia Celular e Molecular, realizada sob a 
orientação científica da Professora Doutora 
Sandra Morais Cardoso (Universidade de 
Coimbra) e supervisão da FCTUC pela 
Professora Doutora Emília Duarte (Universidade 
de Coimbra).  
Daniel Ferreira dos Santos 
2011 
 
 
 
 
Agradecimentos 
 
À Professora Doutora Sandra Morais Cardoso quero agradecer por me ter 
acolhido no seu grupo de trabalho e ter confiado em mim para a realização deste 
trabalho. Quero agradecer sobretudo à orientação e o conhecimento transmitido ao 
longo deste ano. 
Agradeço a todos os colegas do grupo “Molecular Mechanisms of Disease” pelo 
apoio e boa disposição que permitiram um ambiente agradável para a realização deste 
trabalho, e sobretudo aos colegas que mais contribuíram para a minha aprendizagem 
laboratorial, as quais me ensinaram tudo o que hoje sei. Daniela, Raquel e Diana Silva, 
um muito obrigado. 
À Professora Doutora Emília Duarte agradeço todo o apoio fornecido nos 
momentos cruciais de escolhas que se deram ao longo destes dois anos 
Aos meus colegas de Mestrado pelos bons momentos de disposição, e pela 
resposta aos pedidos de ajuda que nunca foram recusados. 
Quero agradecer especialmente aos meus pais, a minha irmã, família e amigos 
por todo o apoio fornecido ao longo deste ano, e pela compreensão nos momentos mais 
difíceis. 
 
 
 
 
 
8 
 
Contents 
Abbreviations .............................................................................................................................. 10 
Resumo ........................................................................................................................................ 12 
Abstract ....................................................................................................................................... 14 
Chapter 1 ..................................................................................................................................... 16 
Introduction ................................................................................................................................ 16 
1.1. Parkinson’s disease and mitochondrial involvement ....................................................... 18 
1.1.1 Critical role of OXPHOS dysfunction in PD ................................................................. 18 
1.1.2. Oxidative stress and PD ............................................................................................. 19 
1.1.3. The role of mitochondrial DNA in PD ........................................................................ 20 
1.2. Familial PD genes and mitochondrial homeostasis .......................................................... 21 
1.2.1. Parkin ......................................................................................................................... 23 
1.2.2. PINK1 ......................................................................................................................... 24 
1.2.3. α-synuclein ................................................................................................................ 25 
1.3. Mitochondrial dynamics ................................................................................................... 27 
1.3.1. Mitochondria as an organelle with a tightly controlled dynamic ............................. 27 
1.3.1.1 Mitochondrial fission........................................................................................... 27 
1.3.1.2 Mitochondrial fusion ........................................................................................... 29 
1.3.1.3. Mitophagy .......................................................................................................... 30 
1.4. Why is mitochondrial dynamics important in neurons? .................................................. 31 
1.4.1. Mitochondrial dynamics in neurodegenerative disorders rather than PD ............... 34 
1.4.2. Mitochondrial dynamics in Parkinson’s disease ....................................................... 35 
1.4.2.1. Available PD models and mitochondrial dynamics ............................................ 35 
1.4.2.2 Role of PINK1 and Parkin in mitochondrial dynamics in PD ................................ 37 
1.4.2.2.1 Modulating mitochondrial shape ................................................................. 37 
1.4.2.2.2. Governing mitochondrial fate ..................................................................... 39 
1.4.2.3. α-synuclein and mitochondrial morphology ...................................................... 40 
1.5. Objectives ......................................................................................................................... 41 
Chapter 2 ..................................................................................................................................... 43 
Materials & Methods .................................................................................................................. 43 
2.1 Biological Material ............................................................................................................. 44 
2.1.1 Cell lines ..................................................................................................................... 44 
2.1.1.1 mtDNA depleted NT2 ρ0 cells ............................................................................. 44 
2.1.1.2 NT2 cybrid cell lines creation .............................................................................. 44 
9 
 
2.1.1.3 Human neuroblastoma cell line SH-SY5Y ............................................................ 45 
2.1.1.4 SH-SY5Y cell line inducible expressing WT α-synuclein ....................................... 45 
2.1.1.5 Human HEK293T cell line .................................................................................... 45 
2.2 Chemicals and Cell media .................................................................................................. 45 
2.3 Subcellular proteome extraction in cultured cells ............................................................ 46 
2.4 Lymphocytes isolation ....................................................................................................... 47 
2.5. Immunoblotting ............................................................................................................... 47 
2.6 Immunocytochemistry ...................................................................................................... 49 
2.6 HEK293T transfection procedure ...................................................................................... 49 
2.5 Fluorometric reactive oxygen species production ............................................................ 50 
Chapter 3 ..................................................................................................................................... 51 
Results ......................................................................................................................................... 51 
3.1. Mitochondrial fragmentation and altered distribution in different PD models .............. 52 
3.2. MPP+ modulates fission and fusion proteins levels in CT cybrids in a distinct manner 
from the observed in basal PD cybrids.................................................................................... 53 
3.3. PD cybrids exhibit decreased mitochondrial levels of the pro-fusion protein Opa1 ....... 55 
3.4. Protein expression in PD patients’ lymphocytes .............................................................. 56 
3.5. Mitochondrial fragmentation in mitochondrial DNA depleted cells, associated with 
aberrant protein expression ................................................................................................... 57 
3.6 Abnormal fusion and fission in ASYN SH-SY5Y overexpressing cells ................................. 60 
3.7 MPP+-induced ROS production is independent of OPA1 mitochondrial levels ................. 64 
Chapter 4 ..................................................................................................................................... 66 
Discussion .................................................................................................................................... 66 
References ................................................................................................................................... 72 
 
 
 
 
 
 
 
 
10 
 
Abbreviations 
 
6-OHDA, 6-Hydroxydopamine 
ASYN, α-synuclein 
ATP, adenosine triphosphate 
BSA, bovine serum albumin 
CCCP, Carbonyl cyanide m-chlorophenyl hydrazone 
CMT2A, Charcot-Marie-Tooth subtype 2A  
CXI, complex I 
Cybrid, cytoplasmatic hybrid 
DHE, dihydroethidium 
Drp1, Dynamin related protein 1 
DTT, Dithiothreitol 
ETC, electron transport chain 
FCCP,  carbonylcyanide-p-trifluoromethoxyphenylhydrazone 
LB, Lewy bodies 
Leucine-rich repeat kinase 2, LRRK2 
Mff, mitochondrial fission factor 
MMP, mitochondrial membrane potential 
MPP
+
, 1-methyl-4-phenylpyridinium 
MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
Mfn1, mitofusin-1 
Mfn2, mitofusin-2 
mtDNA, mitochondrial DNA 
NURR1, Nuclear receptor related 1 protein 
11 
 
OMI/HTRA2, Heat transfer requirement 2 
Opa1, Optic atrophy 1 
OXPHOS, Oxidative phosphorylation 
PBS, phosphate-buffered saline 
PINK1, PTEN-induced putative kinase 1 
PD, Parkinson’s disease 
ROS, reactive oxygen species 
SNpc, substantia nigra pars compacta 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 
 
Resumo 
 
A doença de Parkinson é a segunda doença neurodegenerativa mais comum e a 
doença neurodegenerativa associada ao movimento mais comum. É causada pela perda 
dos neurónios dopaminérgicos na substantia nigra pars compacta levando a um défice 
de dopamina no estriado. Perceber a base molecular da doença de Parkinson tem se 
revelado um grande desafio no campo das doenças neurodegenerativas. Apesar de terem 
sido propostas várias hipóteses para explicar os mecanismos subjacentes a patogenia da 
doença de Parkinson, um crescente corpo de evidencias tem enfatizado o papel da 
disrupção da dinâmica mitocôndrial como um grande contribuidor para a etiopatogenia 
da doença de Parkinson. Tem se vindo a acumular dados que sugerem que uma 
dinâmica mitocondrial anormal se encontra envolvida na disfunção mitocôndrial ou 
medeia a morte neuronal em diferentes modelos da doença de Parkinson. Aliás, a 
integração da fissão, fusão e autofagia mitocondrial forma um mecanismo de 
manutenção de qualidade mitocôndrial da homeostase mitocôndrial na qual defeitos na 
função mitocôndrial têm sido associados à doença de Parkinson. A maioria dos casos 
surge como condição esporádica e os restantes são herdados com mutações em vários 
genes que tem sido ligados a essas formas genéticas da doença. Os estudos de duas das 
proteínas ligadas as formas familiares da doença, nomeadamente a PINK1 e a Parkin, 
forneceram evidências que estas duas proteínas actuam na mesma via regulando a fissão 
e fusão mitocôndria e a mitofagia. Uma vez que uma dinâmica mitocôndrial anormal 
tem sido cada vez mais implicada na patogenia da doença de Parkinson, nesta tese, 
investigámos a regulação da dinâmica mitocôndrial em diferentes modelos celulares da 
doença de Parkinson. Nos observamos que uma diminuta localização mitocôndrial da 
OPA1 leva a um dano da dinâmica mitocôndrial na maioria dos modelos celulares de 
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Parkinson. Para além do mais, a clivagem das isoformas longas da Opa1 parecem ser 
responsáveis pelo padrão de fragmentação observado nos modelos celulares de PD 
esporádicos derivados da mitocôndria. A sobrexpressão da alpha-synucleina induz a 
tubulação da rede mitocondrial com estruturas elongadas que são o oposto do observado 
em modelos celulares de PD. Inesperadamente, a sobrexpressao da Opa1 não resgatou o 
aumento de produção de espécies reactivas de oxigénio induzida pelo MPP
+
. 
Globalmente, as nossas observações sugerem que uma fusão mitocondrial dependente 
da Opa1 desempenha um papel crucial na mediação nas anormalidades mitocôndriais e 
disfunção celular induzida MPP
+
/mtDNA. 
Estes estudos sugerem que a dinâmica mitocôndrial desempenha um papel 
importante na patogenia da doença de Parkinson, e um melhor entendimento destes 
mecanismos podem levar à descoberta de novos alvos terapêuticos para esta doença. 
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Abstract 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder and the most common neurodegenerative movement disorder. It is caused by 
the loss of dopaminergic neurons in the substantia nigra pars compacta leading to a 
dopamine deficit in the striatum. Understanding the molecular basis of PD has proven to 
be a major challenge in the field of neurodegenerative diseases. Although several 
hypotheses have been proposed to explain the molecular mechanisms underlying the 
pathogenesis of PD, a growing body of evidence has highlighted the role of 
mitochondrial dynamics disruption as a major contributor to PD etiopathogenesis. 
Accumulating data suggests that abnormal mitochondrial dynamics is involved in 
mitochondrial dysfunction or mediates neuronal death in different PD models. 
Moreover, integration of mitochondrial fusion, fission and mitochondrial autophagy 
forms a quality maintenance mechanism of mitochondrial homeostasis that defects in 
mitochondrial function have been associated with PD. Most of the cases arise as 
sporadic conditions and the others are inherited with mutations in several genes being 
linked to these genetic forms of PD. Studies of two of the proteins linked to the familial 
forms of the disease, namely PINK1 and Parkin, provided evidence that these two 
proteins act in the same pathway regulating mitochondrial fusion, fission and 
mitophagy. Because abnormal mitochondrial dynamics are increasingly implicated in 
the pathogenesis of PD, in this thesis, we investigated the regulation mitochondrial 
dynamics in different PD cellular models. We observed that a decreased OPA1 
mitochondrial localization-drive mitochondrial dynamics impairment in most cellular 
PD models. Moreover, OPA1 long isoforms cleavage seems to be responsible for 
mitochondrial fragmented pattern observed in sporadic mitochondrial-driven cellular 
PD models. Alpha-synuclein overexpression induces a tubular mitochondrial network 
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with elongated structures that is the opposite of what was observed in mitochondrial PD 
cellular models. Unexpectedly, OPA1 overexpression did not rescued MPP+-induced 
increase in reactive oxygen species (ROS). Overall, our findings suggest that OPA1-
dependent mitochondrial fusion plays a crucial role in mediating MPP+/mtDNA 
induced mitochondria abnormalities and cellular dysfunction. 
These studies suggest that mitochondrial dynamics can play an important role in 
PD pathogenesis, and a better understanding of these mechanisms can lead to the 
discover of new therapeutical targets for this disease. 
 
Keywords: Parkinson’s disease; mitochondrial dysfunction; mitochondrial dynamics; 
mitochondrial fission; mitochondrial fusion; mitophagy 
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Chapter 1 
Introduction 
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Mitochondria, the “power house” of living cells as described before (Banerjee et 
al., 2009), are found virtually in every eukaryotic cell. These are especially complex 
organelles that are involved in a number of cellular functions and are essential for both 
life and death. The main of those functions include: the production of cellular ATP; 
participation in the synthesis of key metabolites; the regulation of apoptosis; calcium 
buffering; and the primary source of endogenous reactive oxygen species (ROS) 
(Delettre et al., 2000, Benard et al., 2007). As there are several assaults, either generated 
in situ or those imposed from extracellular environment, mitochondria are easy targets 
and their functions could be compromised. Therefore, a mitochondrial dysfunction 
results in a smaller supply of cellular energy, a failure in maintaining cellular 
homeostasis, and activation of cell death pathways which could underlie selective 
dopaminergic neurodegeneration in Parkinson’s disease (PD) (Beal, 2005). 
PD is the second most common neurodegenerative disorder after Alzheimer’s 
disease (AD), and the most common neurodegenerative movement disorder. 
Pathologically, it is classically characterized by the loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNpc), leading to a dopamine deficit in the striatum, 
and the presence of proteinaceous cytoplasmatic inclusions called Lewy bodies (LBs) in 
surviving neurons (Forno, 1996). Clinically, PD patients manifest symptoms of 
progressive rigidity, bradykinesia, tremor, and postural instability, as well as symptoms 
involving non-motor brain functions, including cognitive and autonomic functions 
(Lang and Lozano, 1998a, b, Weintraub and Stern, 2005, Barbas, 2006). In PD it is 
known that the loss of the nigral dopaminergic neurons and terminals are responsible for 
movement alterations, although there are indications that several other neuronal 
populations throughout the brain are also affected in this disease (Braak et al., 2004). 
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Nowadays there is no cure for PD, as little is known about the etiopathogenesis of PD, 
and so the pursuit to define disease mechanisms continues.  
 
1.1. Parkinson’s disease and mitochondrial involvement 
In almost 90-95% of all occurrences PD arises essentially as a sporadic 
condition, i.e. in absence of any apparent genetic linkage, and, over the years, several 
theories have been proposed for the etiology of the disease in an attempt to explain the 
why and the how of neurodegeneration in PD. There are several evidences for the 
relation between mitochondrial dysfunction and PD pathogenesis however it is 
debatable if it is the cause or an effect. Even though, it was recently proposed the 
mitochondrial cascade hypothesis for PD (Cardoso, in press).  
 
1.1.1 Critical role of OXPHOS dysfunction in PD 
 
The discovery that exposure to MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine), a selective inhibitor of mitochondrial complex I (CXI) of the 
electron transport chain (ETC), led to a development of progressive and irreversible 
parkinsonism provided strong evidence that mitochondrial dysfunction may be involved 
in the pathogenesis of PD (Langston et al., 1983). This direct relation was further 
established when it was (Schapira et al., 1989) described a CXI deficiency in the 
substantia nigra of PD patients postmortem brains, which was also seen in skeletal 
muscle and platelets (Bindoff et al., 1989, Parker et al., 1989). In agreement, some data 
suggests that sporadic PD is characterized by a systemic decrease in CXI (Penn et al., 
1995, Keeney et al., 2006). Indeed, these authors were able to see that there was an 
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increase in the levels of protein carbonyls (a marker of an oxidative modification of 
proteins) in several catalytic subunits of CXI, which was in agreement with reduced 
electron transfer rates, indicating that the oxidative damage of CXI subunits may lead 
its misassembly and dysfunction. The reason why substantia nigra is more vulnerable to 
this impairment of CXI activity is possible due to increased generation of ROS from 
dopamine metabolism and iron content from dopaminergic neurons (Chinta and 
Andersen, 2008). 
 
1.1.2. Oxidative stress and PD 
 
Mitochondria are the main source for endogenous ROS production (reviewed in 
(Starkov, 2008, Murphy, 2009) and there are evidence of a linkage between oxidative 
stress and neurodegeneration in PD. In addition, the levels of antioxidants and oxidized 
targets are known to be altered in PD, as reviewed before (Jenner, 2003). Together with 
the fact that inhibition of mitochondrial complexes increases free radicals production 
(Orth and Schapira, 2002, Turrens, 2003), it is becoming clear a relation between 
mitochondrial dysfunction and PD. Indeed, an unbalance between exacerbated ROS 
production and/or defective ROS removal results in oxidative damage to mitochondrial 
DNA (mtDNA), proteins and lipids. According to the mitochondrial protein expression 
and/or abundance, it was reported that subunits of CXI was differentially expressed in 
mitochondria enriched fractions from post mortem PD substantia nigra, when compared 
to control (Jin et al., 2006). A reduction of the immunostaining for a mitochondrial 
protein alpha-ketoglutarate was also noted in post mortem PD brain (Mizuno et al., 
1994). Oxidative damage to mtDNA may compromise respiratory chain subunits, which 
are encoded by mtDNA, establishing a vicious circle of oxidative stress and 
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bioenergetic failure, which has been the rationale for the mitochondrial theory of aging 
(Linnane et al., 1989).  
 
1.1.3. The role of mitochondrial DNA in PD 
 
Mitochondria house their own DNA, and it is strongly believed that the 
proximity of mtDNA to ROS generation as a consequence of normal respiratory chain 
function could increase mtDNA mutations (Richter et al., 1988, Ozawa, 1997). Thus, 
the alleged CXI defect in PD brain, and consequent increase in ROS production, may 
affect the mtDNA which encodes 7 of the 46 protein subunits of CXI, making mutations 
in the mtDNA an obvious trigger of PD pathology. Studies with cytoplasmatic hybrids 
(cybrids) cell lines supported this idea of a relation between mtDNA encoded defects 
and PD, showing that CXI defect from PD platelets is transferable into mtDNA 
deficient cell lines (Swerdlow et al., 1996, Gu et al., 1998). Such approach, the use of 
cybrids to investigate the potential of mtDNA from PD to determine the origin of the 
CXI defect, led the authors to suggest that mtDNA in those patients cause the CXI 
deficiency through inherited or somatic mutations. Indeed, these defects were associated 
with increased free radical production, impaired mitochondrial calcium buffer and 
increase susceptibility to MPP
+
 (Sheehan et al., 1997). With these results it could be 
hypothesized that CXI deficit in PD are inherited either from mitochondrial genome or 
from alteration on somatic mtDNA. Moreover, Trimer et al., (2004) using a cybrid 
model of PD reported the formation of fibrillar and vesicular inclusions that replicated 
most antigenic and structural features of LBs (Trimmer et al., 2004). It is important to 
underline that there was no need in this experiment for exogenous protein expression or 
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inhibition of mitochondrial or proteasomal function. In PD, the maternal inheritance 
pattern of mtDNA mutation is rare and may be a mere coincidence (Wooten et al., 1997, 
Swerdlow et al., 1998, Thyagarajan et al., 2000). Although, some studies indicated that 
mtDNA abnormality may contribute to PD, as a mitochondrial 12SrRNA point mutation 
was found in a pedigree with Parkinsonism, deafness and neuropathy (Thyagarajan et 
al., 2000). Another evidence of mtDNA relevance in PD arose when the ablation of the 
mitochondrial transcription factor A gene, which regulates transcription of mtDNA and 
copy number, in nigrostriatal dopaminergic neurons of mice caused the slow 
progressive degeneration of dopaminergic neurons seen in PD (Ekstrand et al., 2007). 
Moreover, this mouse model showed reduced mtDNA expression, respiratory chain 
deficit and neuronal death, leading to progressive, L-dopa-responsive impairment of 
motor functions. Therefore, the role of mtDNA cannot be overruled and further 
investigations are warranted to better understand its role in PD. 
 
1.2. Familial PD genes and mitochondrial homeostasis 
 
As mentioned above, 90-95% of the cases of PD arise as sporadic conditions. 
The others 5-10% of the cases are inherited, and linkage analysis has identified a 
number of PD-associated genes. They usually, but not exclusively, show an early onset 
of symptoms and are in essence clinically indistinguishable from sporadic PD (Bonifati, 
2007, Gasser, 2009). Inherited forms of PD have been linked to 16 familial PD-linked 
genetic loci (PARK1-16), including a–syn, parkin, DJ-1, PINK1 (PTEN-induced kinase 
1), NURR1 (Nuclear receptor related 1 protein), OMI/HTRA2 (Heat transfer 
requirement 2), LRRK2 (Leucine-rich repeat kinase 2), were shown to locate in or 
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interact with mitochondria under certain conditions (Fig. 1) (Arduino et al., 2011, 
Esteves et al., 2011). 
 
 
Figure 1 - Products of PD-associated genes and their role in maintaining mitochondrial 
homeostasis through modulation of mitochondrial dynamics and oxidative stress. Adapted from 
(Henchcliffe and Beal, 2008). 
 
The study of the function and dysfunction of PD genes confirms us the relevance 
of the biochemical alterations found in sporadic PD, i.e., mitochondrial dysfunction, 
oxidative stress and an imbalance in protein homeostasis characterized by an increase in 
protein misfolding and aggregation accompanied by an impaired removal of misfolded 
proteins. Indeed, several of the proteins encoded by them carry out important function 
within mitochondria and/or act to reduce oxidative stress, providing strong evidences 
for a casual involvement of mitochondrial dysfunction and oxidative stress in PD 
pathogenesis. Thus, insight into the function of PD genes can promote our 
understanding of the molecular causes of PD and help to focus research on key 
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biochemical pathways. This also suggests that the mechanisms underlying sporadic and 
familial PD are similar. We will briefly focus on α-synuclein, Parkin and PINK1 
proteins due to their relevance to mitochondrial dynamics.  
 
1.2.1. Parkin 
 
Mutations in the Parkin gene (PARK2) were reported to cause early onset 
juvenile form of autosomal recessive parkinsonism (Kitada et al., 1998). It is suggested 
that Parkin is a RING finger containing protein that acts as an E3 ubiquitin protein 
ligase in the proteasome-mediated degradation of several proteins in vitro (Shimura et 
al., 2000). The loss of the E3 ligase activity has been suggested to result in 
accumulation of toxic substrates leading to the autosomal recessive form of PD 
(Dawson, 2006). It was seen in a Parkin knockout mouse line an increase in striatal 
extracellular dopamine concentrations, reduced synaptic excitability, and a mild, non-
progressive motor deficit at 2–4 months (Goldberg et al., 2003). Surprisingly, no loss of 
dopaminergic neurons was described and, like in most patients with Parkin mutations, 
no inclusion formations were noted in these mice (Goldberg et al., 2003). In a study 
conducted by Palacino and co-workers (2004) Parkin-deficient mice revealed decreased 
levels of several subunits of complexes I and IV. In addition, striatal cells from the mice 
exhibited reduced mitochondrial respiratory capacity and decreased antioxidant capacity 
(Palacino et al., 2004). Recently, it was proposed the hypothesis that Parkin could be a 
key player in the turnover of damaged mitochondria by mitophagy (McBride, 2008), as 
it was shown that Parkin can be recruited to depolarized mitochondria targeting them to 
the destruction by autophagy (Narendra et al., 2008). 
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1.2.2. PINK1 
 
Mutation in phosphatase and tensin homologue (PTEN)-induced putative kinase 
1 (PINK1) are associated with hereditary early-onset of PD (Valente et al., 2004a), as 
certain heterozygous PINK1 mutations may pre-dispose to the development of sporadic 
early-onset PD (Valente et al., 2004b). PINK1 is a serine/threonine kinase which is 
translated in the cytoplasm and imported into mitochondria through an N-terminal 
mitochondrial targeting sequence (Valente et al., 2004a, Silvestri et al., 2005). PINK1 
mutations cause PD possibly due to impairment on the phosphorylation of its substrates, 
probably in mitochondria. These mutations have been reported within and outside the 
kinase domain (Hatano et al., 2004, Valente et al., 2004a), however, the localization of 
PINK1 to the mitochondria is not affected by these mutations (Zhou et al., 2008b). 
Although it is known that PINK1 is imported to mitochondria, as said before, its sub-
mitochondrial localization remains intensely debatable. This topic is crucial for 
identifying its physiological substrates and its mode of action in the context of PD 
pathogenesis. It seems that the majority of the studies demonstrates that PINK1 
localizes in the inner mitochondrial membrane (Silvestri et al., 2005, Gandhi et al., 
2006, Pridgeon et al., 2007), while other suggest that it associates with the 
intermembrane space (Silvestri et al., 2005, Plun-Favreau et al., 2007, Pridgeon et al., 
2007) or even the outer mitochondrial membrane (Gandhi et al., 2006) with the kinase 
domain facing the cytoplasm (Zhou et al., 2008b). The depletion of PINK1 in cultured 
cells results in abnormal mitochondrial morphology and membrane depolarization. 
Similar mitochondrial alterations are present in primary cells from patients with PINK1 
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mutations (Exner et al., 2007) suggesting that PINK1 plays an important role in 
mitochondrial maintenance. There is also a study in which seems to exists an important 
role for PINK1 protecting mitochondria against oxidative stress by phosphorylating the 
mitochondrial chaperone protein TRAP1 (Pridgeon et al., 2007). There is no doubt that 
more studies in this area are needed, although there is a certainly that both proteins 
modulate mitochondrial dynamics including fusion/fission which will be further 
mentioned in detail concerning PD pathogenesis.  
 
1.2.3. α-synuclein 
 
Three different missense mutation in α-synuclein (ASYN) gene (PARK1& 4 
locus), a duplication and triplication of the ASYN gene locus lead to dominantly 
inherited early-onset of PD (Polymeropoulos et al., 1997, Kruger et al., 1998, Singleton 
et al., 2003, Zarranz et al., 2004). Although its physiological function is still quite 
unknown, it is known that ASYN is a presynaptic protein that is present in an 
aggregated form in LB’s in PD due to the presence of its hydrophobic non-amyloid beta 
component domain. It has been described that familial mutation and over-expression of 
this protein accelerates this so-called ASYN protofibrilis (Conway et al., 1998, Conway 
et al., 2000, Fredenburg et al., 2007). The selective toxicity of ASYN to dopamine 
neurons (Xu et al., 2002) maybe in part explained by the stabilization of the toxic 
ASYN protofibrilis by dopamine adducts (Conway et al., 2001). There are various 
mechanisms proposed to explain ASYN toxicity, one of those includes mitochondrial 
dysfunction. However both are hallmarks implicated in PD pathogenesis it was not clear 
until recently that these two processes are interrelated and complement each other in 
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disease pathogenesis. Indeed, recent evidences suggests this interplay in which mice 
harboring human A53T ASYN mutant shown mitochondrial accumulation of human 
ASYN and exhibit mitochondrial degeneration associated with increased mtDNA 
damage and impaired activity of the electron transport chain complex IV cytochrome 
oxidase (Martin et al., 2006). Studies in yeast, where abrogation of mtDNA inhibited α-
synuclein-induced ROS formation and apoptosis (Buttner et al., 2008), highlighted the 
requirement of mitochondria in mediating the toxicity of α-synuclein. Mitochondrial 
association of ASYN in cells was also linked to oxidation of mitochondrial proteins and 
increased levels of calcium and nitric oxide (Parihar et al., 2008). It was interesting to 
note that mice lacking ASYN exhibited alterations in membrane lipids and reduced 
activities of the electron transport complexes I and III in mitochondria (Ellis et al., 
2005), suggesting that ASYN has a physiological role in mitochondria, and that the 
mitochondrial deficits observed in transgenic animals may be due to toxic gain-of-
function of over-expressed or mutated ASYN present in mitochondria. Recently, is was 
shown that human ASYN N-terminal 32 amino acids contain a cryptic mitochondrial 
targeting signal, which is important for mitochondrial targeting of ASYN (Devi et al., 
2008). It was also seen, in human dopaminergic neurons, that accumulation of wild-type 
ASYN in mitochondria caused reduced mitochondrial CXI activity and increased ROS 
production. Although, these defects occurred in an early time point in dopaminergic 
neurons expressing familial with A53T mutation as compared with wild-type ASYN 
(Devi et al., 2008). In this work it was also shown that ASYN interacts with CXI in the 
inner mitochondrial membrane. In fact, the content of ASYN in purified mitochondria 
from substantia nigra were several-fold higher in PD compared to healthy individual, 
suggesting that mitochondrial accumulation of ASYN may contribute to the CXI defects 
of the disease (Devi et al., 2008). Therefore, the interaction process of ASYN with 
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mitochondria is quite complex and impacts mitochondrial physiology to affect normal 
functioning of dopaminergic neurons. 
 
1.3. Mitochondrial dynamics 
 
1.3.1. Mitochondria as an organelle with a tightly controlled 
dynamic 
 
What was once thought to be an isolated and rigid structure organelle, 
mitochondria became now highly dynamic organelle that constantly divides (fission) 
and fuse (fusion) with each other (Chan, 2006). Indeed, this highly dynamic and 
orchestrated process of mitochondrial fusion and fission affects, besides morphology, 
the size, number, length and even mitochondrial function and distribution. This 
phenomenon regulated by a delicate balance between these two opposing processes is 
important in order to maintain the integrity of mitochondria, electrical and biochemical 
connectivity, in mitochondrial turnover, and in aggregation, stabilization, and protection 
of mtDNA (Westermann, 2002). 
 
1.3.1.1 Mitochondrial fission 
 
For the mitochondrial division, both the inner and outer membrane need to fise 
and the mtDNA and other critical mitochondrial contents need to be redistributed to the 
daughter mitochondria, so that the parental gives rise to two isolated, small, round 
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organelles. Although the precise mechanism of mitochondrial fission is not fully 
elucidated, it involves at least two proteins in mammals: a 
large GTPase, dynamin-related protein 1 (Drp1, also 
referred to as DLP1) and a small molecule, Fis1 (Chan, 
2006, Knott et al., 2008) (Fig. 2). Drp1, a protein that 
controls membrane tabulation and fission, although 
primarily cytosolic is recruited to the outer mitochondrial 
membrane. Once there, Drp1 has the ability to oligomerize 
and form large complexes with other proteins (like Fis1) 
(Hoppins et al., 2007). It is believed that once a ring-like 
complex structure is formed along the mitochondrial 
surface, Drp1 uses GTP hydrolysis to constrict and twist 
tubule to initiate fission (Smirnova et al., 2001). As 
mentioned before, Fis1 is involved in mitochondrial fission as it acts as a receptor to 
recruit Drp1 to mitochondria. This mitochondrial outer membrane protein, resident on 
the surface of mitochondria (James et al., 2003), appears to be a limiting factor during 
the process of mitochondria fission as, in mammalian cells, knockdown of Fis1 blocks 
mitochondrial fission without affecting Drp1 localization to mitochondria (Lee et al., 
2004). Recently, another protein, Mff, was suggested to be involved in mitochondrial 
fission as the knockdown of the same caused mitochondrial elongation and resistance to 
CCCP-induced fragmentation (Gandre-Babbe and van der Bliek, 2008). However, 
further studies are necessary to elucidate the potential role of this protein in the 
recruitment of Drp1 to mitochondria. Therefore, this process of mitochondrial fission 
seems to be very useful and crucial for mitochondrial function as it facilitates equal 
segregation of mitochondria into daughter cells in cellular division and to enhance 
Figure 2 – Drp1 and Fis1 
function and localization 
during mitochondrial 
fission. Adapted from 
(Knott et al., 2008). 
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distribution of mitochondria along cytoskeletal tracks. It also has an important role in 
the targeting of damaged segments of mitochondria to the autophagic process, playing a 
housekeeping role in the cell, as it will be mentioned later. 
 
1.3.1.2 Mitochondrial fusion 
 
On the other side, mitochondrial fusion, in mammalian cells, is mediated in part 
by the outer membrane dynamin-like GTPases mitofusin-1 and -2 (Mfn1 and Mfn2) and 
the inner membrane optic atrophy protein (Opa1) 
(Fig. 3) (Cerveny et al., 2007, Detmer and Chan, 
2007b). Although both Mfn1 and Mfn2 have the 
same location and appear to play similar roles in 
mitochondrial fusion, they function independently 
of each other, even having different rates of GTP 
hydrolysis (Ishihara et al., 2004) (Fig. 4). Indeed, it 
was reported that these two proteins could form 
homo-oligomeric and hetero-oligomeric 
complexes, during mitochondrial fusion, and thus 
tether outer membranes of neighboring 
mitochondria together (Ishihara et al., 2004, Zuchner et al., 2004). The inner membrane 
protein OPA1, that faces intermembrane space, has been propose to be primarily 
involved in the inner membrane fusion in a process that requires Mfn1, but not Mfn2 
(Cipolat et al., 2004). Like mitochondrial fission, fusion seems to be required for a 
normal mitochondrial function as this process is likely to protect function by providing 
Figure 3 – Mitochondrial outer and 
inner membrane fusion controlled by 
Mfn1/2 and OPA1 respectively. 
Adapted from (Knott et al., 2008) 
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a chance for mitochondria to mix their contents, thus enabling protein complementation, 
mtDNA repair and equal distribution of metabolites. 
 
 
Figure 4 – Proteins reponsable for the modulation of mitochondrial dynamics and cellular 
localization of the same. Adapted from (Winklhofer and Haass, 2010) 
 
1.3.1.3. Mitophagy 
 
As mentioned before, mitochondrial dysfunction can be a key determinant in cell 
death as this organelle provides critical functions for cell survival. Indeed, it is 
necessary an orchestrated mechanism capable of selectively remove damaged 
mitochondria that are functionally impaired or have accumulated mtDNA mutation that 
potentiates ROS generation. The process responsible for this is denominated autophagy. 
It is a process in which cellular components are isolated by engulfment into 
autophagosomes. Further these autophagosomes fuse with lysosomes which contain 
hydrolytic enzymes that break down cellular components. Generally this process is 
activated during nutrient deprivation so that the products can be recycled into more 
urgently needed molecules. However, autophagy can have a housekeeping role in 
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maintaining quality control by turning over organelles, like mitochondria, and 
degrading protein aggregates. So mitochondria can be targeted for degradation in a 
process called mitophagy. Although this process is not new, it had remained unclear 
whether mitophagy can selectively degrade dysfunctional mitochondria. In a study 
performed by Kanti and Klionsky it was reported that selective mitophagy was 
regulated independently from bulk autophagy (Kanki and Klionsky, 2008). It was also 
described that mitochondrial fission could target mitochondria to degradation. Indeed, it 
was shown in pancreatic b-cells and COS7 cells that mitochondrial fission can yield 
uneven products in which one of the daughter mitochondrion was depolarized, much 
less like to fuse and had reduced levels of OPA1 protein, and eventually was 
autophagocytosed (Twig et al., 2008). Supporting this find it was also stated that to 
mitophagy occur there must be a loss of fusion and the presence of fission. In the base 
of this theory is the fact that the overexpression of OPA1, Fis1 RNAi, and Drp1 
dominant-negative expression all reduced level of mitophagy. Although mitochondrial 
fragmentation is suitable for mitophagy, it is not a sufficient signal for this process 
(Narendra et al., 2008, Twig et al., 2008).  
 
1.4. Why is mitochondrial dynamics important in neurons? 
 
Changes in the mechanisms that mediate mitochondrial dynamics can lead to 
different defects in neurons (Fig. 5). Some of the reasons for the particular importance 
of mitochondria fusion and fission in neurons possible rely on their unique features such 
as their post-mitotic state and their long processes with higher energy requirements. 
Indeed, this high energy demands to support their survival and specialized function may 
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lead this type of cell vulnerable to mitochondrial dynamics defects. In agreement with 
this theory specific mutations in fusion related genes result in human neuropathies 
(Delettre et al., 2000, Zuchner et al., 2004), while mutations in both fission and fusion 
related genes have been associated with central nervous system disease (Waterham et 
al., 2007, Brockmann et al., 2008). Indeed, these neurons with long axons (like 
peripheral sensory neurons and motor neurons) are preferential degenerated when 
 
Figure 5 – Neuronal dysfunction as consequence of defects in mitochondrial dynamics. (A) In 
wild type neurons, mitochondria are distributed along the neurons and function normally with a 
normal performance of their function. (B) In neurons where there is no fusion there is an 
increase in fragmented mitochondria, some of those dysfunctional, which are not distributed 
along the cytokeletal tracks. (C) When there is no fission mitochondria forms a tubular network 
difficult to transport to axons and dendrites, with accumulation of damaged mitochondria in the 
soma. (D) When the motility is affected there is not a good distribution of these organelles along 
the neurons. (E) Without the process necessary for the turnover of mitochondria there is an 
accumulation of damaged mitochondrial along the neurons. Addapted from (Chen and Chan, 
2009). 
 
 
mitochondrial dynamics are compromised leads due to their high energy requirement 
for several aspects of neuronal physiology. In fact, synaptic transmission requires high 
level of energy and a sufficient number of mitochondria to be present at synaptic sites 
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so that the plasma-membrane-potential could be maintained, synaptic neurotransmitter 
could be released and reuptake, and to build-up a reserve pool of vesicles for prolonged 
or high-frequency firing. The dynamic processes of mitochondrial fission/fusion are 
intimately and critically involved in the formation of synapses and dendritic spines, 
where exist a high demand of ATP. While the unbalance of mitochondrial fission/fusion 
towards fission leads to an increase in synapse formation, a decrease in the same leads 
to a loss of mitochondria from dendritic spines and a reduction of synapse formation (Li 
et al., 2004). The absence of the mitochondrial fission protein Drp1 has been shown to 
prevent mitochondria from distributing to synapses and to lead to synaptic dysfunction 
(Verstreken et al., 2005).This might be linked to the need of smaller mitochondrial units 
which presumably are more easily transported over long distances as, e.g., required in 
axonal transport. Other mitochondrial feature that is very important for normal neuronal 
physiology is the Ca
2+
 buffering that prevents excitotoxicity by an excessive free-Ca
2+
 
load in neurons. On the other hand, the process of fusion is crucial for the maintenance 
of mtDNA that cannot take place without this process (Rapaport et al., 1998). In fact, 
fusion of mitochondria has been directly implicated in preventing the accumulation of 
damaged mtDNA (Nakada et al., 2001, Ono et al., 2001). As it was shown recently, 
mitochondrial fission appears to be critical to mtDNA maintenance (Parone et al., 2008) 
and so we can find that in mitochondrial dynamics a delicate balance is very important 
as the coordination of these processes maintain and protect mtDNA. This is very 
important in neurons and neurodegenerative diseases as it was shown that mtDNA 
mutations accumulate in the brain with age (Corral-Debrinski et al., 1992). Neurons are 
also particularly sensitive to the impairment of the transport of mitochondria through 
the axons and dendrites so that these could reach sites of increased energy requirement. 
They are transported both in anterograde and retrograde directions, in a process 
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regulated in part by cytoskeletal and mitochondrial proteins, and several intrinsic 
component of mitochondrial bioenergetics, like ATP synthesis or changes in 
mitochondrial membrane potential, can impair this transport (Rintoul et al., 2003, Miller 
and Sheetz, 2004). This suggests a link between mitochondrial bioenergetic functions 
and mitochondrial transport and distribution. In addition, disruption of mitochondrial 
movement has been noted in excitotoxicity and oxidative stress conditions (Rintoul et 
al., 2003), two factors implicated in cellular stress and neuronal death. 
 
1.4.1. Mitochondrial dynamics in neurodegenerative disorders 
rather than PD 
 
There are several mutations in mitochondrial fission/fusion genes in humans that 
result in very specific neurodegenerative diseases. Regarding the mitochondrial fusion 
proteins, mutations in Mfn2 cause Charcot-Marie-Tooth subtype 2A (CMT2A), which 
involves axonal degeneration of motor and sensory neurons (Zuchner et al., 2004, 
Kijima et al., 2005). Mutations in Opa1, other mitochondrial fusion protein, cause the 
most common form of optic atrophy, autosomal dominant optic atrophy (ADOA) 
(Alexander et al., 2000). Concerning the mutations in mitochondrial fission proteins, a 
dominant negative mutation in the human Drp1 gene resulted in elongated and tangled 
mitochondria concentrated at perinuclear region (Waterham et al., 2007). The patient 
carrying this mutation died shortly after birth and displayed some symptoms resembling 
those of ADOA and CMT2A, emphasizing the importance of the fission machinery in 
neuronal maintenance. 
It is interesting to note that there are some human genetic mutations that do not 
affect mitochondrial morphogenesis, as the others described above, but cause disease 
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through a fission/fusion-independent manner. Examples of this are some Mfn2 mutants 
that retain the ability to promote mitochondrial fusion (Detmer and Chan, 2007a). This 
could indicate that Mfn2 has other pathogenic roles not related to mitochondrial fusion. 
There are several studies suggesting other functions for this protein, like mitochondrial 
trafficking (Baloh et al., 2007) and regulating Ca
2+
 uptake and signaling by tethering 
mitochondria to endoplasmatic reticulum (de Brito and Scorrano, 2008), which 
disruption could lead to peripheral axon degeneration and neuronal death. Although, it 
remains necessary the creation of animal models so it could be distinguishable the 
contribution of the various functions of the fission/fusion genes in disease pathogenesis. 
 
1.4.2. Mitochondrial dynamics in Parkinson’s disease 
 
One of the most accepted reasons for the vulnerability of the dopaminergic 
neurons from substantia nigra to changes in mitochondrial dynamics is the lower basal 
mitochondrial content compared to other midbrain neurons (Liang et al., 2007). This 
evidence could contribute to the selective vulnerability of these neurons to external or 
internal toxic stimuli that affect mitochondrial fission, fusion and mitophagy, 
compromising mitochondrial homeostasis during PD pathogenesis. 
 
1.4.2.1. Available PD models and mitochondrial dynamics  
 
Through the widely used models to mimic PD pathogenesis it was already 
described the existence mitochondrial dynamics imbalance. Indirect observations using 
a cytoplasmatic hybrid (cybrid) model of PD showed that PD cybrid cells contained a 
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significantly increased percentage of mitochondria that were enlarged or swollen and 
had a pale matrix with few remaining cristae (Trimmer et al., 2000). This mitochondrial 
morphology in PD cybrids, whose mitochondria are proceeding from platelets of PD 
patients, was also seen by Esteves and coworkers in a similar cybrid model, suggesting 
that there could be impairment in mitochondrial fission (Esteves et al., 2008). 
The first evidence demonstrating mitochondrial fragmentation induction by 
toxins used to study PD, was the finding that both CXI inhibitors rotenone and MPP
+
 
induced mitocondrial fission in rat dopaminergic cell line N27 (Barsoum et al., 2006). 
Following studies continued to report mitochondrial fragmentation following 
administration of CXI inhibitors like 6-Hydroxydopamine (6-OHDA)l(Gomez-Lazaro 
et al., 2008), MPP
+
 (Meuer et al., 2007, Endo et al., 2009, Wang et al., 2011c) and 
rotenone (Benard et al., 2007, Mortiboys et al., 2008, Plecita-Hlavata et al., 2008, 
Sandebring et al., 2009, Thomas et al., 2011). Interestingly, some of these authors went 
further and showed that the CXI inhibition-induced mitochondrial fragmentation was 
Drp1-dependent, as Drp1 silencing or its dominant-negative mutant expression 
prevented the mitochondrial morphological changes and the cell death induced by the 
toxins (Benard et al., 2007, Meuer et al., 2007, Gomez-Lazaro et al., 2008, Wang et al., 
2011c). Together, these results highlight mitochondrial fragmentation as an early and 
upstream event mediating CXI inhibition-induced toxicity. However, it was reported 
that chronic exposure to rotenone significantly increased mitochondrial branching and 
length in human skin fibroblasts (Koopman et al., 2005). The discrepancy between these 
results may rely in the different duration of the toxic stimuli, e.g. acute vs. chronic, 
toxin concentration, or different cell lines, which may affect differently mitochondrial 
morphology. Therefore, in further necessary studies using PD-linked toxins to study 
mitochondrial morphology, careful experimental design should be performed in order to 
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accurately mimic PD pathology and enable a proper analysis of the mitochondrial 
network in this disease. 
 
1.4.2.2 Role of PINK1 and Parkin in mitochondrial dynami cs in PD 
 
Until now, the strongest evidence of the role of mitochondrial dynamics in PD 
aroused from studies in which the manipulation of some genes associated with familial 
PD affected mitochondrial dynamics in several models and tissues. As previously 
described, PINK1 and Parkin are proteins that have an important role in mediating 
mitochondrial function and morphology. 
 
1.4.2.2.1 Modulating mitochondrial shape 
Back in 2003, the first studies describing mitochondrial structural alterations 
associated with parkin mutants arouse. Using Drosophila Parkin mutant flies it was 
reported that muscle mitochondria had abnormal morphology, including swollen or 
fragmented mitochondria with disrupted cristae, a phenotype that was rescued by 
overexpression of wild-type Parkin (Greene et al., 2003, Pesah et al., 2004). 
Surprisingly, no major morphological abnormalities in striatal mitochondria of parkin -
/- mice were later reported (Palacino et al., 2004), an observation that would serve as a 
template for the discrepancies of the results arising from the models to study PINK1 and 
Parkin effect on mitocondrial morphology, that would then emerge. 
The first detailed studies unraveling PINK1 and Parkin role in mitochondrial 
morphology regulation were preformed through genetic manipulations in Drosophila. 
Initially, loss of PINK1 or Parkin function in Drosophila resulted in similar 
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mitochondrial morphological abnormalities, including enlarged mitochondria with 
fragmented cristae. Surprisingly, Parkin overexpression was able to rescue PINK1 
mutant mitochondrial morphology defects, but not vice versa, suggesting that PINK1 
and Parkin take part in the same pathway in which PINK1 acts upstream of Parkin in 
regulation of mitochondrial morphology (Clark et al., 2006, Park et al., 2006, Yang et 
al., 2006). Latter findings, still in Drosophila, revealed how PINK1/Parkin pathway 
exerts its effect in mitochondrial morphology. It was shown that the Drp1 loss of 
function was lethal in PINK1 or Parkin mutants, as Drp1 overexpression suppressed the 
mitochondrial morphological abnormalities described before (Deng et al., 2008, Poole 
et al., 2008, Yang et al., 2008, Park et al., 2009). Interestingly, loss of function of the 
proteins involved in the mitochondrial fusion process, like Mfn and Opa1, were also 
able to restore mitochondrial morphology in PINK1 and Parkin mutants, suggesting that 
PINK1/Parkin pathway stimulates mitochondrial fission and/or inhibits mitochondrial 
fusion.  
However, conformity between the results reported in Drosophila and findings in 
vertebrates was not achieved. In HeLa cells PINK1 knockdown induced mitocondrial 
fragmentation and reduced/altered mitochondrial cristae in mammalian cells, 
abnormalities that were rescued by wild type PINK1 and Parkin overexpression, but not 
Parkin mutant’s (Exner et al., 2007). Observations in primary fibroblasts from patients 
with PINK1 mutations have also shown mitochondrial fragmentation. Moreover, PINK1 
or Parkin down-regulation in mammalian cells was again reported to induce comparable 
mitochondrial fragmentation (Dagda et al., 2009, Lutz et al., 2009). As Drp1 
knockdown was able to reverse this phenotype, demonstrating that increased 
mitochondrial fission is associated with PINK1/parkin depletion, Mfn2 and Opa1 
overexpression could also rescue mitochondrial phenotype (Lutz et al., 2009). Further 
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studies reported again that PINK1 loss of function increased mitochondrial fission 
(Wood-Kaczmar et al., 2008, Cui et al., 2010, Heeman et al., 2011, Wang et al., 2011b), 
as human wild type PINK1 overexpression produces a pro-fusion effect in the 
mitochondrial network (Cui et al., 2010).  
Strikingly, even between mammalian models there’s still some controversy as in 
recent studies PINK1 or Parkin overexpression resulted in mitochondrial fragmentation, 
and inactivation of these proteins resulted in elongated mitochondria (Gautier et al., 
2008, Sandebring et al., 2009, Cui et al., 2011, Pacelli et al., 2011, Yu et al., 2011), in 
agreement with the former Drosophila studies. Overexpression of Drp1 or the 
knockdown of Opa1 reversed the mitochondrial elongation induced by PINK1 RNAi, as 
overexpression of PINK1 or Parkin were also suppressed mitochondrial elongation 
induced by Drp1 knockdown (Yu et al., 2011). 
 
1.4.2.2.2. Governing mitochondrial fate 
Beyond the “simple” regulation of mitochondrial morphology, through 
interactions with the mitochondrial fission/fusion machinery, an important role for the 
PINK1/Parkin pathway has been attributed at the mitochondrial quality control level. 
Upon mitochondrial damage, PINK/Parkin pathway have been reported to 
promote poly-ubiquitination Mfn1 and Mfn2, through Parkin interaction, leading to its 
turnover by UPS, independently of the autophagic pathway (Chan et al., 2011, Glauser 
et al., 2011). The degradation of these mitochondrial outer membrane fusion proteins 
leads to an impairment of mitochondrial fusion which, upon physiological conditions, 
can exert a selective removal of damaged mitochondria by autophagy (mitophagy). 
Indeed, Parkin was suggested to prevent refusion of depolarized mitochondria, product 
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of a division process, through elimination of the proteins involved in the outer 
mitochondrial membrane fusion, Mfn1 and Mfn2 (Tanaka et al., 2010). 
The dependence on this pathway to promote mitophagy has been extensively 
described as PINK1 and Parkin silencing leads to lower ubiquitination of the 
mitochondrial proteins Mfn1 and Mfn2 upon mitochondrial damage, leading to 
accumulation of defective mitochondria (Gegg et al., 2010). Mutations in PINK1 and 
Parkin also impairs ubiquitination of mitofusins in human fibroblasts (Rakovic et al., 
2011). Moreover, a study in Drosophila has shown that Parkin requires functional 
PINK1 to correctly be recruited to dysfunctional mitochondria and promote their 
degradation, through Mfn1/2 degradation (Ziviani et al., 2010). 
The parkin-mediated autophagy was shown to be prevented upon inhibition of 
Drp1-mediated mitochondrial fission, emphasizing the importance of these 
fission/fusion proteins in mitochondrial quality control (Tanaka et al., 2010). 
Importantly, it was recently revealed that Parkin also interacts and ubiquitinates Drp1, 
signaling this protein for degradation at the UPS (Wang et al., 2011a) 
 
1.4.2.3. α-synuclein and mitochondrial morphology  
 
A relation between mitochondrial morphology and ASYN was early described 
as overexpression of ASYN resulted in abnormal large mitochondria displaying 
vacuolization of the cristae (Hsu et al., 2000). Still, at the time, no direct interaction was 
established between them. Nowadays it is clear that ASYN interacts with mitochondria. 
It is extensively described its transport to this organelle and its accumulation in the 
same (Martin et al., 2006, Li et al., 2007, Cole et al., 2008, Devi et al., 2008, Nakamura 
et al., 2008, Parihar et al., 2008, Shavali et al., 2008, Liu et al., 2009, Chinta et al., 2010, 
Zhu et al., 2011). Some of these reports also highlight ASYN ability to associate with 
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proteins like complex I and the adenylate translocator, impairing their activity. ASYN 
transgenic mice developed mitochondrial pathology, as mitochondria contained ASYN 
and were shrunken, swollen, or vacuolated (Martin et al., 2006). Moreover it has been 
recently suggested that this association between ASYN and mitochondria has a critical 
role in the regulation of mitochondrial morphology. Indeed, according to two recent 
studies, it seems that this association drives mitochondrial fission by inhibition of the 
fusion process (Kamp et al., 2010, Nakamura et al., 2011). This ability of ASYN was 
demonstrated to be independent of the fusion/fission machinery and seems to rely 
simply in its direct interaction with mitochondrial membranes. In other study, 
overexpression of ASYN has been reported to induce mitochondrial morphological 
deformation as swollenness, cristae loss and vacuolation (Zhu et al., 2011). 
 
1.5. Objectives 
 
Taken together, the studies reviewed here provide several evidences that 
perturbations in mitochondrial dynamics could underline the selective degeneration 
observed in PD pathogenesis. However it is important to note that the processes that 
mediate mitochondrial dynamics - fission, fusion and mitophagy - are not isolated and 
independent, and there are several aspects of these machinery that need to be elucidated 
in order to get a better understanding in the mechanisms that are responsible for the 
imbalanced mitochondrial dynamics that are known to occur in PD. In this thesis we 
performed several studies in order to get a clear understanding of this pathway. We used 
different cellular PD models that mimic sporadic (cybrids), familial PD (-synuclein 
overexpressing cells), or PD patients lymphocytes in order shade a light and elucidate 
the conflicting data in PD. We also direct manipulated the fusion machinery (OPA1 
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overexpression) in a way that could rescue mitochondrial function in a PD model. Our 
work allowed us to gain a better understanding of the pathway mediating mitochondrial 
dynamics in PD. 
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Chapter 2 
Materials & Methods 
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2.1 Biological Material 
 
2.1.1 Cell lines 
 
2.1.1.1 mtDNA depleted NT2 ρ0 cells  
 
NT2 human neuroblastoma cell line containing mtDNA (ρ+), purchased from 
Stratagene (La Jolla, CA) was depleted from mtDNA by long-term ethidium bromide 
exposure as described by Swerdlow and co-workers (1997). Cells were grown in 75 
cm2 tissue culture flasks maintained in a humidified incubator at 37ºC and 5% CO2. 
 
2.1.1.2 NT2 cybrid cell lines creation  
 
To create the cybrid cell lines for this study, we used the teratocarcinoma cell 
line lacking mtDNA (NT2-Rho0 cell line) that does not possess a functional ETC and is 
autotrophic for pyruvate and uridine (Swerdlow et al., 1997). In brief, NT2-Rho0 cells 
were repopulated with platelet mitochondria from either healthy individuals or PD 
patients (CT cybrids and PD cybrids, respectively). Seven days after fusion, cybrid cells 
were placed in selection medium containing 10% dialyzed fetal calf serum and lacking 
pyruvate and uridine, as previously described (Swerdlow et al., 1997, Cardoso et al., 
2004).These conditions result in the selective death of Rho0 cells that have not been 
repopulated with donor mitochondria. After selection was complete, cybrid cells were 
switched to cybrid expansion medium. Cells were grown in 75 cm2 tissue culture flasks 
maintained in a humidified incubator at 37ºC and 5% CO2. 
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2.1.1.3 Human neuroblastoma cell line SH -SY5Y 
 
SH-SY5Y human neuroblastoma cells were purchased from ATCC. Cells were 
grown in 75 cm2 tissue culture flasks maintained in a humidified incubator at 37ºC and 
5% CO2. 
 
2.1.1.4 SH-SY5Y cell line inducible expressing WT α-synuclein 
 
The generation of a stable cell line inducible expressing WT ASYN was 
described previously (Vekrellis et al., 2009). Briefly, naïve SHSY-5Y cells were 
transfected with the Tet-Off vector and selected with 500 µg/mL G418. Determination 
of the inducibility of the resistant clones was determined by transient transfection of a 
pTRE-LUC vector, in the presence or absence of dox (2µg/mL) in TET-Off-approved 
medium, and one clone (2-22) was further used for generation of stable pTRE-ASYN 
expression. 
 
2.1.1.5 Human HEK293T cell line  
 
Human HEK293T cells were obtained from ATCC. Cells were grown in 75 cm2 
tissue culture flasks maintained in a humidified incubator at 37ºC and 5% CO2. 
 
2.2 Chemicals and Cell media 
 
MPP
+
 was purchased from Sigma. DMEM medium was obtained from Gibco-
Invitrogen. Optimem medium was obtained from Gibco-Invitrogen. Non-dialyzed and 
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dialyzed fetal bovine serum was obtained from Gibco-Invitrogen. NT2 ρ0 cell growth 
medium consisted of Optimem supplemented with 10% heat inactivated fetal bovine 
serum, 200 µg/ml sodium pyruvate, 150 µg/ml uridine, and 100 IU/ml penicillin and 50 
µg/ml streptomycin. NT2 cybrid selection medium consisted of Optimem supplemented 
with 10% non-dialyzed heat inactivated fetal bovine serum and penicillin–streptomycin. 
Cybrid expansion medium consisted of Optimem supplemented with 10% heat 
inactivated fetal bovine serum and penicillin–streptomycin. MPP+ medium consisted of 
cybrid expansion medium with 1 mM MPP
+
. SHSY-5Y cell growth medium consisted 
in DMEM and Ham´s F12 medium with 10% supplemental fetal bovine serum and 100 
IU/ml penicillin and 50 μg/ml streptomycin. HEK283 cells growth consisted in DMEM 
supplemented with 10% fetal bovine serum and penicillin–streptomycin. SHSY-5Y 
cells were cultured in RPMI 1640, 10% fetal bovine serum. Stable cells inducible over-
expressing WT ASYN were maintained in 250 lg/mL G418 and 50 lg/mL Hygromycin 
B. ASYN expression was switched off with dox (2 µg/mL). Stock cultures were kept in 
the presence of dox. Analysis in stable cells inducible over-expressing WT ASYN was 
performed 4 days after removal of dox from cell’s medium. 
 
2.3 Subcellular proteome extraction in cultured cells 
 
In order to obtain pure mitochondrial and cytosolic protein extracts, protein 
subcellular extraction was performed in cell culture using ProteoExtract® Subcellular 
Proteome Extraction Kit from Calbiochem®, according to the manufacturer's protocol. 
Briefly, each extraction buffer is sequentially incubated with cell pellet taking 
advantage of the differential solubility of certain subcellular compartments in the 
specific buffer. After incubation, the subcellular compartment solubilized in the 
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respective extraction buffer is separated from cell pellet by appropriate centrifugation 
force. 
 
2.4 Lymphocytes isolation 
 
Venous blood was collected by venipuncture in K2EDTA-containing tubes. 
Lymphomonocytes were isolated by Ficoll-Histopaque 1077 density gradient 
centrifugation. Briefly, blood samples were carefully layered on Ficoll-Histopaque 1077 
and centrifuged
 
for 20 min at 2500rpm at room temperature, in a swing-out rotor, 
without brake. Lymphomonocytes were collected from the interface between serum and
 
Ficoll-Histopaque 1077 gradients and washed once in PBS. The solution was then 
centrifuged to pellet the cells for 10 min at 1500rpm, at room temperature. Cells were 
the lysated with in buffer containing 25 mM HEPES, 1 mM EDTA, 1 mM EGTA, 2 
mM MgCl2, protease inhibitors (commercial protease inhibitor cocktail from Sigma), 
0.1 M PMSF (Sigma), 0.2 M DTT (Sigma), 1% Triton X-100 , 2mM ortovanadate and 
50 mM sodium fluoride. 
 
2.5. Immunoblotting 
 
For the analysis of total protein levels, individual cybrid cell lines were scraped 
in buffer containing 25 mM HEPES, 1 mM EDTA, 1 mM EGTA, 2 mM MgCl2, 
protease inhibitors (commercial protease inhibitor cocktail from Sigma), 0.1 M PMSF 
(Sigma), 0.2 M DTT (Sigma), 1% Triton X-100 , 2mM ortovanadate and 50 mM 
sodium fluoride. Cell suspensions were frozen three times in liquid nitrogen and 
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centrifuged at 20,000 g for 10 min at 4 ºC. The resulting supernatants were removed and 
stored at −80°C. Protein concentrations were determined by the Bradford method and 
equal amounts of protein (50 µg) were used for immunoblotting. For the SDS-PAGE 
experiments samples were resolved by electrophoresis in SDS polyacrylamide gels and 
transferred to PVDF membranes (Millipore, Billerica, MA, USA). Non-specific binding 
was blocked by gently agitating the membranes in 5% non-fat milk or 5% BSA, for 
phosphorilated proteins, and 0.1% Tween in TBS for 1h at room temperature. The blots 
were subsequently incubated with the respective primary antibodies overnight at 4°C 
with gentle agitation (1:1000 Polyclonal Rabbit anti-phospho-Drp1 (Ser616) antibody 
from Cell Signaling Technology; 1:750 Polyclonal Rabbit anti-Fis1 antibody from 
Imgenex; 1:520 Rabbit Polyclonal anti-Opa1 antibody from Abcam; 1:10,000 
monoclonal anti-alpha-tubulin antibody from SIGMA; 1:200 Polyclonal Rabbit anti-
Drp1 antibody from Santa Cruz Biotechnology, Inc.; 1:200 Polyclonal Rabbit anti-Mfn1 
antibody from Santa Cruz Biotechnology, Inc.; 1:200 Polyclonal Rabbit anti-Tom20 
antibody from Santa Cruz Biotechnology, Inc.; 1:500 Monoclonal Mouse anti-Mfn2 
antibody from Abnova; 1:1000 mouse; 1:500 Monoclonal Mouse anti-glyceraldehyde-
3-phosphate dehydrogenase from Millipore). Blots were washed with TBS containing 
0.1% non fat milk and 0.1% Tween three times (each time for 10 min), and then 
incubated  with the appropriate horseradish peroxidase- conjugated secondary antibody 
for 2 h at room temperature with gentle  agitation. After three washes specific bands of 
interest were detected by developing with an alkaline phosphatase enhanced chemical 
fluorescence reagent (ECF from GE Healthcare). Fluorescence signals were detected 
using a Biorad Versa-Doc Imager, and band densities were determined using Quantity 
One Software. 
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2.6 Immunocytochemistry 
Cells were all plated at density of 0.05x10
6
 and after incubation periods cells 
were washed twice with PBS and fixed for 30 min at room temperature using 4% 
paraformaldehyde. The fixed cells were washed again with PBS, permeabilized with 
0.2% Triton X-100, and blocked with 3% BSA. The permeabilized cells were incubated 
with primary antibody (1:100 polyclonal rabbit anti-Tom20 from Santa Cruz 
Biotechnology; and 1:400 mouse monoclonal anti-α-sunuclein from Santa Cruz 
Biotechnology). Afterward cells were incubated 1h with appropriate secondary antibody 
(1:200 alexa fluor 594 and 488 from Molecular probes, Eugene, OR, USA). Finally 
cells were washed in PBS, incubated for 5 minutes with Hoechst 33342 (15mg/L in 
PBS, pH 7.4) in the dark. Cells were visualized by confocal microscopy. 
 
2.6 HEK293T transfection procedure 
 
HEK293T cells were transfected using FuGENE® 6 Transfection Reagent 
according to manufacturer’s protocol. The Reagent:DNA ratio used was 6:1 (µl, for 
transfection reagent, and µg for DNA, respectively). The Opa1 (WT) construct was a 
kind gift from Xiongwei Zhu, Case Western Reserve University, Cleveland, OH 44106, 
USA. The expression vector for Myc-tagged wild-type OPA1 was based on pCMV-Tag 
vector (Stratagene). 
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2.5 Fluorometric reactive oxygen species production 
 
ROS production was measured using dihydroethidium (DHE), a dye that in 
cytoplasm exhibits blue fluorescence, however, once this probe is oxidized to ethidium, 
it intercalates within DNA, staining the cell nucleus a bright fluorescent red. HEK293 
cell were plated at the density of 0.05x10
6
 in 48-well plates and transfected the next day 
for 48h. After the 24h treatment for the last 24h of transfection, cells were washed once 
with PBS (at 37ºC), and the incubated with 7.5 µM DHE (from a stock solution of 1 
mM in DMSO) in Krebs medium, at 37ºC, and put in the incubator in light-protected 
conditions, for 1h at 37ºC. 
Fluorescence was monitored every 5 min for 1h, at 37ºC, by using a Spectramax 
GEMINI EM fluorocytometer (Molecular Devices), with excitation and emission 
wavelengths corresponding to 518 and 605 nm, respectively. After the measure, Krebs 
medium was removed and the cells were cells were scraped in buffer containing 25 mM 
HEPES, 1 mM EDTA, 1 mM EGTA, 2 mM MgCl2, and protease inhibitors (0.1 M 
PMSF, 0.2 M DTT, 1% Triton X-100 and 1:1,000 dilution of a protease-inhibitor 
cocktail) for posterior protein quantification by the Bradford method. 
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Chapter 3 
Results 
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3.1. Mitochondrial fragmentation and altered distribution in 
different PD models 
 
In order to investigate the morphology and distribution of the mitochondrial 
network in the cybrids it was preformed an immunostaining against the mitochondrial 
protein Tom20. PD cybrids exhibited a more perinuclear distribution of the 
mitochondrial network when compared to control cybrids, with and apparent loss of 
mitochondrial interconnectivity (Fig. 6). This inference is based on the appearance of 
fragmented mitochondria nearby nucleus with disorganized mitochondrial network that 
no longer connect with each other. It was also tested the effect of acute MPP
+ 
exposure, 
a CXI inhibitor. Incubation with 1mM of MPP
+
 for 24 hours fragmented mitochondrial 
network in a great extent, resulting in the appearance of round-shaped disconnected 
perinuclear mitochondria. Taken together, PD cybrids exhibit an intermediary 
mitochondrial network between CT cybrids and MPP
+
 treated CT cybrids. 
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Figure 6 – Mitochondrial fragmentation and altered distribution in PD cellular models. 
Representative immunofluorescence pictures evidencing mitochondrial network in CT and PD 
Cybrids, under basal conditions, and in MPP
+
-treated CT cybrids (1mM, 24 hours). 
Immunostaining was performed against the mitochondrial protein Tom20. PD cybrids 
mitochondrial network morphology is placed between the pronounced mitochondrial 
fragmentation and perinuclear distribution in MPP
+
-treated CT cybrids and the interconnected 
well distributed CT cybrids mitochondrial network. Green: Tom20, Blue: Hoechst. 
(Magnification x63) 
 
3.2. MPP+ modulates fission and fusion proteins levels in CT 
cybrids in a distinct manner from the observed in basal PD 
cybrids 
 
Observed the abnormal mitochondrial network in PD cybrids and MPP+ treated 
CT cybrids we next asked whether there was a disturbance of the proteins involved in 
the mitochondrial fission and fusion process. The immunoblot performed from total 
cellular lysates revealed a balance of the protein levels between CT and PD cybrids 
except in levels of the pro-fusion protein Mfn2 that were increased in PD cybrids (Fig. 
7). Treatment of CT cybrids with the CXI inhibitor MPP
+
 resulted in a different 
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modulation of protein levels, significantly decreasing the fusion-stimulatory 
phosphorylation of Drp1 at Ser616 and Mfn2 levels, when compared to basal CT 
Cybrids. Strikingly, MPP+ treatment modulates the conversion of the isoforms of the 
mitochondrial protein Opa1 involved in the fusion process. Indeed, it is observed a 
conversion of the denominated long isoforms (LI) into the short isoforms (SI), 24h after 
treatment with MPP
+
. Summarizing, the acute CXI inhibition appear to regulate the 
levels of the proteins involved in mitochondrial fission fusion process differently from a 
chronic CXI inhibition. 
 
Figure 7 – Accute MPP+ treatment modulates mitochondrial fission/fusion proteins levels 
unlike the chronic pathological state, the PD cybrid. Representative immunoblot (A,C) and 
quantification analysis (B,D) revealed that  Mfn2 levels are increased in PD cybrids when 
compared to CT cybrids. MPP
+
 treatment of CT cybrids reduces the levels of the fusion protein 
Mfn2 and the phosphorylation of the fission protein Drp1 (Ser616) (B). MPP
+
 also modulates 
the conversion of Opa1 long isoforms (LI) into short isoforms (SI) (C). Data represent mean ± 
SEM values derived from, at least, three independent determinations. (*p < 0.05; **p < 0.01; 
***p <0.001, significantly different when compared to CT cybrid group; Student’s t-test). 
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3.3. PD cybrids exhibit decreased mitochondrial levels of the pro-
fusion protein Opa1 
 
Given that slight differences in the protein levels were seen between CT and PD 
cybrids we next asked whether the subcelullar localization of the proteins was similar. 
For this purpose CT and PD cybrid cells were fractionated in mitochondrial and 
cytosolic extracts. The results from the fractionation process revealed that PD cybrids 
have a significant reduction in mitochondrial levels of the pro-fusion protein Opa1, 
when compared to CT cybrids (Fig. 8). However, no significant differences were seen in 
the levels of the other proteins in both fractions, inclusive in Mfn2 mitochondrial levels. 
 
 
Figure 8 – Decreased Opa1 mitochondrial levels in PD cybrids. CT and PD cybrids cells 
were harvested and fractionated into mitochondrial and cytosolic fractions. Representative 
immunoblot (A) and quantification analysis (B) of the proteins levels involved in mitochondrial 
fission and fusion revealed a decrease in the mitochondrial levels of the pro-fusion Opa1 in PD 
cybrids. Equal protein amounts (50 µg) were loaded and confirmed with Tubulin and Tom20 for 
the cytosolic and mitochondrial fractions, respectively. The purity of the mitochondrial and 
cytosolic fractions is confirmed by the negligible contamination each fraction with the marker 
of the other fraction. Data represent mean ± SEM values derived from three independent 
determinations. (* P < 0.05, when compared to CT cybrid group; Student’s t-test). 
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3.4. Protein expression in PD patients’ lymphocytes 
 
In order to get a better insight from how the mitochondrial network morphology 
is regulated in vivo, mitochondrial fission/fusion proteins were analyzed in PD patients, 
comparing to age-matched healthy subjects. Total lysates from lymphocytes, isolated 
from venous blood, were immunobloted and no significant statistical variations were 
seen between PD and CT subjects (Fig. 9), although we could see an increase in pDRP1 
levels and a decrease in OPA1 levels, which point towards an increase in mitochondrial 
fragmentation. 
 
 
Figure 9 – Basal expression of mitochondrial fission and fusion proteins in PD 
lymphocytes. Lymphocytes were isolated form PD and age-matched healthy subjects and total 
lysates were immnunobloted. Representative immunoblot (A) and quantification analysis (B) of 
the proteins levels involved in mitochondrial fission and fusion revealed no statistical 
significant differences in the total protein levels of PD subjects, relative to controls. Equal 
protein amounts (50 µg) were loaded and confirmed with Gapdh. Data represent mean ± SEM 
values derived from three independent determinations. 
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3.5. Mitochondrial fragmentation in mitochondrial DNA depleted 
cells, associated with aberrant protein expression 
 
To gain a better understand of the contribution of mtDNA to the mitochondrial 
network, immunocytochemistry against the mitochondrial protein Tom20 was 
performed in mtDNA depleted NT2 cell line. Upon basal condition NT2 ρ0 cell display 
a pronounced fragmented mitochondrial network with very small round mitochondria 
instead of a reticulated network seen in NT2 CT cybrids (Fig. 10, 6).  
 
 
Figure 10 – Mitochondrial fragmentation in mitochondrial DNA depleted cells. Representative 
immunofluorescence pictures evidencing mitochondrial network in NT2 cells, containing or not mtDNA, under basal 
conditions, or treated with FCCP (10µM, 2 hours). Immunostaining was performed against the mitochondrial 
protein Tom20. NT2 ρ0 cells exhibit mitochondrial fragmentation when compared to NT2 CT cybrids. Green: Tom20.  
 
Indeed, an impaired fusion or increased fission may cause fragmentation of the 
mitochondrial network in the absence of mtDNA. To distinguish between these 
possibilities, we evaluated in NT2 ρ0 cells the proteomics of the proteins involved in the 
mitochondrial fission and fusion process. In agreement with previous observations in 
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PD cybrids (Fig.8), cells lacking mtDNA revealed a significant reduction in 
mitochondrial levels of the pro-fusion protein Opa1 long isoforms (LI) (Fig. 11). 
Moreover, it was observed a decrease in Mfns in the mitochondrial fration (Fig.11). Our 
results strongly suggest that the organelles are unable to fuse. 
 
A 
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Figure 11 – Fusion and Fission protein expression levels in mitochondrial DNA depleted 
cells. Cells were harvested and fractionated into mitochondrial and cytosolic fractions. 
Representative immunoblot (A) and quantification analysis (B) of the proteins levels involved 
in mitochondrial fission and fusion revealed a decrease in the mitochondrial levels of the pro-
fusion Opa1 and Mfn1 in . Equal protein amounts (50 µg) were loaded and 
confirmed with Tubulin and Tom20 for the cytosolic and mitochondrial fractions, respectively. 
The purity of the mitochondrial and cytosolic fractions is confirmed by the negligible 
contamination each fraction with the marker of the other fraction. Data represent mean ± SEM 
values derived from two independent determinations. 
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3.6 Abnormal fusion and fission in ASYN SH-SY5Y overexpressing 
cells 
 
To further verify the physiological relevance of the involvement of ASYN in 
modulating mitochondrial morphology, mitochondrial morphology were monitored by 
imaging of cells, incubated with Tom20. When wild-type ASYN was overexpressed in 
SH-SY5Y cells, a decreased mitochondrial fragmentation was observed (Figure 12). In 
order to validate our results and experimental conditions (4 days overexpressing ASYN) 
we treated both cells with FCCP, and observed an increase in the mitochondrial 
fragmentation pattern.  
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Figure 12 –Mitochondrial fragmentation in wt ASYN overexpressing cells. Representative 
immunofluorescence pictures evidencing mitochondrial network in SH-SY5Y cells, 
overexpressing or not wt α-synuclein, under basal conditions, or treated with FCCP (10µM, 2 
hours). Immunostaining was performed against the mitochondrial protein Tom20 and α-
synuclein. Green: Tom20, Red: α-synuclein, Blue: Hoechst. 
 
Overexpression of ASYN affected the expression levels and subcellular 
localization of Mfn1, Mfn2, Opa1 and pDrp1 (Fig. 13). Accordingly to our 
immunocytochemistry data, we observed a decrease in pDRP1 and increased in 
mitochondrial OPA1 and Mfn1 expression and localization. Our results clearly indicate 
that ASYN induced a decrease in mitochondrial fission or stimulates mitochondrial 
fusion. 
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Figure 13 – Fusion and Fission protein expression levels in wt ASYN overexpressing cells. 
Cells were harvested and fractionated into mitochondrial and cytosolic fractions. Representative 
immunoblot (A) and quantification analysis (B) of the proteins levels involved in mitochondrial 
fission and fusion revealed a decrease in the mitochondrial levels of the pro-fusion Opa1 and 
and Tom20 for the cytosolic and mitochondrial fractions, respectively. The purity of the 
mitochondrial and cytosolic fractions is confirmed by the negligible contamination each fraction 
with the marker of the other fraction. Data represent mean ± SEM values derived from two 
independent determinations. 
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3.7 MPP+-induced ROS production is independent of OPA1 
mitochondrial levels 
 
Mitochondria are the primary source for endogenous ROS, and a significant 
increase in ROS levels could be detected in HEK293T cells after 24 h of treatment with 
MPP
+
 (Fig. 14). MPP
+
-treated HEK293T cells show an increase in superoxide radical 
production. When challenged with rotenone, a complex I inhibitor, HEK293T cells 
increase significantly superoxide radical production. Interestingly, MPP
+
 and rotenone 
co-treatments decreased the detection of ROS levels, probably due to the loss of cell 
numbers after this trigger. 
To explore the relationship between MPP
+
-induced mitochondrial fragmentation 
and ROS production, we also measured ROS levels in OPA1 overexpressing HEK293T 
cells treated with MPP
+
 for 24h. Basal level of ROS was similar in nontreated OPA1 
overexpressing cells compared with control cells. Unexpectedly, MPP
+
-induced ROS 
production was not dependent on mitochondrial OPA1 levels. Cells treated with MPP
+
 
that overexpressed OPA1 showed an increase in ROS production (Fig. 14). These 
findings indicate Opa1 overexpression doesn’t rescue MPP+ induced ROS production in 
HEK293T cells. 
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Figure 14 – Opa1 overexpression does not protect against MPP+ induced ROS production. 
Quantification of ROS production (A) revealed that MPP
+
 treatment increases ROS production 
which cannot be rescued by previous Opa1 overexpression. Transfection efficiency was 
confirmed by western blot analysis (B).  Asterisks point for the appearance of an additional 
staining of Opa1 after transfection, which is also reacts to C-myc immunostaining. Equal 
protein amounts (50 µg) were loaded and confirmed with Gapdh. Data represent mean ± SEM 
values derived from two independent determinations. TR: Transfection reagent. 
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Chapter 4 
Discussion 
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The data presented in this work supports the idea that an abnormal mitochondrial 
morphology and distribution is a consequence of OXPHOS deficiency. Mitochondria in 
our PD cellular model exhibit an intermediary phenotype between healthy state and 
acute CXI inhibition-induced severe mitochondrial fragmentation (Fig. 6). Although 
MPP
+
 treatment of our CT cybrids (1mM, 24h) resembles CXI activity deficiency of our 
PD cybrids (Esteves et al., 2008), fission/fusion proteins’ levels modulation is very 
different. Indeed, our PD cybrids exhibits a reduction of mitochondrial Opa1 levels and 
accumulation of the Mfn2 levels, both proteins involved in the mitochondrial fusion 
process (Fig. 7, 8). Treatment of CT cybrids with MPP+ also modulates Opa1 levels, 
however it significantly reduces Mfn2 levels and the fission-stimulatory 
phosphorylation of Drp1 at Ser616.  
Several CXI inhibitors were described to induce mitochondrial fragmentation in 
a Drp1- dependent manner (Benard et al., 2007, Gomez-Lazaro et al., 2008, Wang et al., 
2011c). Indeed, Wang and colleagues have recently shown that MPP+ mediates Drp1-
dependent mitochondrial fragmentation in SH-SY5Y cells as the attenuation of 
mitochondrial fragmentation by Drp1 knockdown almost prevents the decrease of 
mitochondrial membrane potential, calcium handling disruption, increased ROS 
generation and deficient mitophagy, placing mitochondria fragmentation as an upstream 
event mediating MPP
+
-induced toxicity (Wang et al., 2011c). Our results with MPP
+
 
treatment of CT cybrids are, in some extent, in agreement with the previous study. They 
had described that at 24h after MPP
+
 treatment, during which they had seen a biphasic 
increase in Drp1 levels, Drp1 levels are similar to control, which is also seen in our 
MPP
+
 treated CT cybrids (Fig. 7). Although it was shown that Drp1 plays an important 
role in cell death, it might not be the only player, and therefore Wang and co-workers 
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study lacks information regarding mitochondrial proteins involved in mitochondrial 
fusion.  
Increasing studies have been highlighting a tight regulation of the proteins 
involved in the mitochondrial fusion process in neurodegeneration, namely Opa1 and 
Mfn1 & 2. Indeed, decreased expression of these proteins have been described in 
neurodegenerative diseases, namely in AD and HD (Wang et al., 2008, Wang et al., 
2009, Manczak et al., 2011, Shirendeb et al., 2011). 
Between our chronic and acute mitochondrial model of PD it appears to be a 
nexus at Opa1 and Mfn’s levels modulation. Indeed, our PD cybrids exhibits reduced 
mitochondrial Opa1 isoforms levels (Fig. 7, 8) and MPP+ treatment modulates Opa1 
levels by converting Opa1 long isoforms into the short ones (SI) (Fig. 7). Along with 
the fragmented mitochondrial phenotype observed here (Fig. 6), disorganization of 
mitochondrial cristae structure, mitochondrial membrane potential reduction and 
mitochondrial cytochrome c release were also described in our PD cybrids (Esteves et 
al., 2008), in agreement with results observed upon Opa1 siRNA-mediated knockdown 
in HeLa cells (Olichon et al., 2003, Griparic et al., 2004). Indeed, it was suggested that 
loss of mitochondrial Opa1 accelerates cytochrome c release and causes a block in 
mitochondrial fusion, placing apoptotic mitochondrial fragmentation downstream of 
these events (Arnoult et al., 2005). 
On the other side, whereas in our acute MPP
+
-model there is a propensity for a 
reduction in Mfns levels (Fig. 7), Mfns levels in our PD cybrids remain identical, or 
higher (Fig. 7, 8). In the field of Mfns’ levels regulation it was been extensively 
described that upon mitochondrial damage Mfn1 & 2 are ubiquitinated by Parkin and 
degraded in a proteasome dependent manner (Tanaka et al., 2010, Chan et al., 2011). 
Therefore, it is possible that upon MPP
+
 induced damage in CT cybrids mainly Mfn2 is 
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ubiquitin tagged and degraded by proteasome leading to the decreased Mfn2 levels. 
However, in our PD cybrids impairment in the UPS (Martins-Branco unpublished work) 
may either prevent ubiquitination of Mfns or inhibit their proteasome mediated 
degradation, culminating in the accumulation of defective fragmented mitochondria. 
Future experiments accessing Mfns ubiquitination can quickly elucidate this hypothesis. 
Moreover, our results in PD patients lymphocytes, show a trendline towards an 
increase in pDRP1 and a decrease in OPA1 levels (Fig. 9), although no statistical 
significance was obtained with such small sample. These results are in accordance with 
what we observed in PD cybrids, obtained after fusion of PD patients platelets with 
mtDNA depleted cells. 
Interestingly, Opa1 was shown to be crucial for mtDNA replication and 
distribution as silencing of Opa1 variants led to mtDNA depletion and to altered 
mtDNA distribution throughout the mitochondrial network (Elachouri et al., 2011). As 
the already described cellular deficits of our PD cybrid cell lines are consequences of 
the inheritance of PD patient mtDNA (Esteves et al., 2008), targeting Opa1 function 
seems appropriate to maintenance of mitochondrial genome integrity in a cellular model 
of a disease. In order to address this issue we performed experiments in cells without 
mtDNA, and observed a similar pattern of mitochondrial morphology and intracellular 
localization as in PD cybrids (Fig. 10 and 6). Although, we observed a comparable 
decrease in mitochondrial OPA1 levels, these cells have more dramatic proteomic 
alterations, like a decrease in mitochondrial Mfn 2 and 1 (Fig. 11). Indeed, NT2 0 cells 
FCCP, what could be explained by a dramatic alteration towards mitochondrial 
fragmentation under basal conditions (Fig. 10). 
Studies using dominant optic atrophy (DOA) patients fibroblasts with inhibited 
mitochondrial fusion, caused by mutation in the OPA1 gene, showed disturbed 
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oxidative metabolism with impaired mitochondrial ATP synthesis after treatment with 
CXI inhibitor (Zanna et al., 2008). 
Since familial PD can also be caused ASYN gene duplication/triplication, which 
leads to enhanced protein levels of ASYN (Singleton et al, 2003) and patients with 
sporadic PD show an increase of ASYN mRNA and oligomers as was observed in our 
sporadic PD model, PD cybrids (Esteves et al., 2011) we wanted to access the effect of 
wt ASYN in mitochondrial fragmentation/elongation. It was previously described that 
ASYN mediated mitochondrial fragmentation independently of mitochondrial fusion 
and fission proteins (Kamp et al 2010). Our results, using the same cell line, but with a 
stable tranfection of wt ASYN, show a decrease of mitochondrial fragmentation (Fig. 
12) with a decreased expression of the fission protein pDRP1 and increases in 
mitochondrial fusion proteins, OPA1, Mfn1. Our findings suggest that ASYN gene 
duplications or triplications may lead to increased amounts of ASYN inside the 
mitochondria (Esteves et al., unpublished work), which may promote mitochondrial 
fusion in order to dilute toxic ASYN oligomers. More studies with cells overexpressing 
ASYN need to be done in order to fully understand the contradictory results obtained by 
Kamp and co-workers (2010) showing that increased amounts of ASYN bind to 
mitochondria inhibiting mitochondrial fusion and therefore trigger disease pathology.  
While it remains to be determined whether and how mtDNA-induced changes in 
bioenergetic function cause mitochondrial fragmentation, we demonstrated that a 
compromised OXPHOS causes an excessive mitochondrial fragmentation triggered by a 
cleavage of the OPA1 LI (Fig. 7 and 8). However, the involvement of mitochondrial 
fragmentation and perinuclear distribution in OXPHOS-mediated impairments in 
mitochondrial membrane potential, calcium handling, ROS generation and mitophagy 
as well as eventual cell death are still undisclosured. Indeed, the attenuation of 
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mitochondrial fragmentation by OPA1overexpression did not prevent MPP+-induced 
ROS production (Fig. 14). It was previously described that DRP1 knockdown prevented 
MPP+-mediated ROS production (Wang et al., 2011). Indeed, Opa1 up-regulation 
already shown to restore mitochondrial morphology and to protect neurons against 
excitotoxicity (Jahani-Asl et al., 2011). Although no changes in Opa1 levels and 
distribution were seen upon exposure to NMDA, this protein was required for 
calpastatin-mediated neuroprotection, placing Opa1 downstream of calpain activation 
following an excitotoxic stimulus. Our cybrid cellular model also presents show an 
exacerbate calpain activation, which may be mediating OPA1 clevadge (Esteves et al., 
2011). 
Although we still need to address OPA1/mitochondrial fusion involvement in 
OXPHOS-mediated mitochondrial membrane potential depletion, mitochondrial 
calcium buffering, and mitophagy, we strongly believe that changes in mitochondrial 
dynamics and turnover might render neurons susceptible to degeneration in PD. 
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